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Abstract: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any
benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and
implications of these negative results and the implications for clinical practice and future research.
Trial registration: ClinicalTrials.gov: NCT00692770. Registered 5 June 2008. This study has been completed.
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Main text
The prevention and the delay of relapse of hepatocellular
carcinoma (HCC) after curative treatment remain a major
challenge. Recently the sorafenib as adjuvant treatment in
the prevention of recurrence of hepatocellular carcinoma
(STORM) study reported in Lancet Oncology by Bruix and
colleagues [1] investigated whether sorafenib is an effect-
ive adjuvant treatment after resection or ablation in
patients with early HCC. The study postulated a benefit of
sorafenib as adjuvant treatment in the prevention of
tumor recurrence and, therefore, its ability to increase
patient survival. Both the primary endpoint— recurrence-
free survival— and secondary endpoints — time to recur-
rence and overall survival — were not reached. Despite
being negative, we believe that the study has several posi-
tive implications for clinical research.
First, it has important implications for the design of
future adjuvant trials in HCC and for the choice of the drug
to be tested. The goal of adjuvant treatment is to reach for
a cure. When tumors are emerging from a pro-tumoral
underlying disease, decreasing the risk of both recurrence
and de novo tumors is an additional challenge. Whether
these two goals are achievable with a unique drug and strat-
egy is an open question in HCC. Assuming side effects for
a limited period of time, most active treatments should
effectively target tumor residues. In contrast, long-term
preventive treatment of the underlying disease would re-
quire drugs with a very good tolerance profile fitting
chronic administration. The latter is a challenge in the drug
development paradigm in which molecules are developed
for maximum efficacy in the advanced setting. However, as
illustrated by this trial and others, these results are quite
often not translatable to the adjuvant setting. Undetectable
tumors may exist as vascularized micrometastases, non-
vascularized clusters of tumor cells, and isolated or even
circulating tumor cells [2]. Whereas the benefit of an anti-
angiogenic agent on residual vascularized tumors may be
obvious, it is clearly speculative for the other tumor cell
populations that lack proper evaluation models [3]. Unlike
bevacizumab, a specific anti vascular endothelial growth
factor A (VEGF-A) antibody, sorafenib has antiangiogenesis
and antiproliferative proprieties [4]. It could be expected
that sorafenib will be more potent to block residual or
metastatic tumor cells independently of its antiangiogenic
action. In addition, sorafenib could prevent the growth and
progression of micrometastases by inhibiting de novo
angiogenesis. Nevertheless, no robust preclinical or clinical
data have yet confirmed such hypotheses, especially in a
very heterogeneous tumor such as HCC.
In the STORM trial, no beneficial or detrimental effect
of sorafenib has been reported besides a trend towards
increased time to recurrence, which may reflect a positive
impact of sorafenib on tumor relapse and/or prevention of
de novo tumors. Investigating post-recurrence treatment
strategies and outcomes may also yield valuable informa-
tion in the perspective of global HCC management.
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Second, adjuvant strategy in HCC crucially needs
improved stratification to better define the population
who could benefit from adjuvant treatment from the
population who does not need further therapeutic inter-
vention. Considering the results of the present study and
the preceding considerations, new trials directed to pa-
tients with a higher risk of relapse than the STORM
population might be worthwhile to redeem the effect of
sorafenib as adjuvant treatment. Nevertheless, improved
staging combining histological and biological parameters
would be an important step forward discriminating sub-
groups prognosis and therapeutic interventions.
Finally, in the present time of exploding medical costs,
adjuvant trials should consider the cost-effectiveness of
long-term treatments, which emphasize the need of better
stratifying patients to focus on the appropriate population
[5]. As hypothesized in the STORM trial, a 30% increase
in recurrence-free survival may be worth the cost of
several years of an expensive drug before it goes generic.
Moreover, when positive, such trials could also lead to
follow-up studies better defining the targeted patient pop-
ulations. Considering the intrinsic medical and biological
differences between adjuvant and advanced settings, it
may be time to consider new tools and new arguments to
develop drugs in adjuvant settings.
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